Navigation Links
Significant Generic Erosion Will Cause Sales of Dyslipidemia Drugs to Decline by $3.6 Billion by 2016
Date:3/19/2008

Statins Will Continue to Dominate Market Despite Patent Expiries and Increased Use of Fixed-Dose Combinations, According to a New Report from

Decision Resources

WALTHAM, Mass., March 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sales of dyslipidemia therapies will decline from $28 billion in 2006 to $24.4 billion in 2016 owing to significant generic erosion, triggered particularly by the 2006 U.S. patent expiry of Merck's Zocor and the U.S. and European patent expiries of Pfizer's Lipitor beginning in 2010.

The new Pharmacor report entitled Dyslipidemia finds that statins will continue to dominate the dyslipidemia drug market by claiming more than 70 percent patient share in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. However, the sales share of statins will decline from $21 billion in 2006 to $7.8 billion in 2016 owing to generic erosion and greater use of fixed-dose combination therapies that offer dual modes of action and/or modulate high-density lipoprotein (HDL) in addition to low- density lipoprotein (LDL) cholesterol. The fixed-dose combinations class will capture 30 percent of the dyslipidemia market in 2016.

The report also finds that physicians will increasingly prescribe treatment aimed at aggressive LDL targets in high-risk patients, which will benefit more potent agents such as AstraZeneca's Crestor and add-on therapies such as Merck/Schering-Plough's Zetia/Ezetrol. Aggressive treatment will also boost uptake of novel LDL-lowering therapies such as lapaquistat, Takeda's novel squalene synthase inhibitor, which will be used in polypharmacy regimens.

"Although statins are entrenched as the first-line therapy of choice for the vast majority of dyslipidemia patients and have achieved success in lowering both LDL and the risk of heart attacks, the prevalence o
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Carnegie Mellon study shows just listening to cell phones significantly impairs drivers
2. NeurogesX to Present at Susquehanna Financial Groups 2nd Annual SIGnificant Options in Healthcare Conference
3. Novavax CEO to Present at Susquehannas Second SIGnificant Options in Healthcare Conference
4. Abaxis, Inc. to Present at the Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
5. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
6. Advanced Life Sciences to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference
7. Significant Growth for Pinstripe Leads to Need for Larger Facility
8. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
9. AAAS symposium to address significant effects of the male parent in reproductive success
10. Peter G. Peterson Commits $1 Billion Toward Solving Americas Most Significant Economic Challenges
11. Surprising New Research Indicates that Significant Numbers of Children as Young as 11 are Engaging in Sexual Activity and that Dating Violence and Abuse are Part of Their Relationships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2015 Doctors in Novara, Italy have ... predictor of outcomes for people with mesothelioma than other ... of the new study on the Surviving Mesothelioma website. ... of Eastern Piedmont followed the cases of 172 ... excess lung fluid. , “Persistent lung expansion after ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 After a ... processes, customer service, pricing and long-term strategy, Blood Centers ... vendor of choice for member centers’ testing needs. , ... and represents more than 30 percent of the U.S. ... meeting. , “BCA is committed to drive cost savings ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Over the ... acquisitions among leading vendors seeking to expand their geographic ... market is expected to reach $6.2 billion by 2019 ... North America including the U.S. and Canada and a ... devices. However developing regions such as Asia-Pacific including China ...
(Date:3/2/2015)... March 02, 2015 LegitScript, ... healthcare certification programs, including those for Internet ... supplement safety and classification, has launched a ... eyeglasses. The new program, called iCareRx ... transparency regarding the identity of the owner/operator ...
(Date:3/2/2015)... Prairie, WI (PRWEB) March 02, 2015 ... sciences consultancy focused on quality, regulatory and technical ... role as Chief Operating Officer. , Before ... of experience leading R&D teams in all aspects ... held leadership positions at Covidien (Medtronic), Regulatory Compliance ...
Breaking Medicine News(10 mins):Health News:New Research Links Talc Treatment Response with Mesothelioma Prognosis, According to Surviving Mesothelioma 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 3Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3Health News:LegitScript Launches Certification Program for Internet Eyeglass Sellers 2Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2
... ANN ARBOR, Mich. Some patients with large tumors on ... and radiation over surgery to remove the voice box. ... Center found that a single round of chemotherapy could identify ... "Organ preservation studies have excluded these patients because their tumors ...
... a lump is found in the breast of an adolescent ... breast cancer is rare in adolescents, and the vast majority ... that are related to hormones. A recent Loyola University ... Roentgenology suggests that a breast ultrasound examination might eliminate ...
... Texas, June 25 Leading business and health care ... the Texas Coalition for Worksite Wellness, "Call for Coverage ... provide employees with comprehensive smoking cessation benefits. The ... with comprehensive smoking cessation coverage by an additional 100,000 ...
... State and Federal Healthcare Policy and Regulatory Team , ... of the largest law firms in Florida and one ... today the expansion of its Healthcare practice with significant ... healthcare professionals have joined the practice in the firm,s ...
... is available in German . , ... requires time- and labor-intensive molecular-biological procedures. Established methods are ... burden is very low, for example during a phase ... types of micro-pumps without movable parts, scientists from the ...
... Health Plan One of 17 Platinum-Level Award winners , ... Plan have been honored by the National Business Group on ... innovative programs that promote a healthy workplace and for helping ... their own health and well-being. , , UPMC was ...
Cached Medicine News:Health News:U-M study finds voice box can be preserved, even with the largest cancers 2Health News:What should a teenage girl do if she finds a lump in her breast? 2Health News:Business, Health Care Leaders Call on Texas Employers to Cover Smoking Cessation Benefits for an Additional 100,000 People by 2010 2Health News:Business, Health Care Leaders Call on Texas Employers to Cover Smoking Cessation Benefits for an Additional 100,000 People by 2010 3Health News:Akerman Senterfitt Announces Expansion of Healthcare Practice 2Health News:Akerman Senterfitt Announces Expansion of Healthcare Practice 3Health News:Virus filters for medical diagnosis 2Health News:UPMC and UPMC Health Plan Recognized by National Business Group on Health As a Leading Employer Promoting Healthy Lifestyles for Its Employees 2Health News:UPMC and UPMC Health Plan Recognized by National Business Group on Health As a Leading Employer Promoting Healthy Lifestyles for Its Employees 3
(Date:3/2/2015)... , March 2, 2015  SI-BONE, Inc., a ... fusion for certain disorders of the sacroiliac (SI) joint ... that more than15,000 iFuse procedures have now been performed ... Adoption of the iFuse procedure continues to ... performed the procedure in the United States ...
(Date:3/2/2015)... 2015 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... milestone payment from GSK related to advancing the Phase 2/3 ... polyneuropathy (FAP).  "We are very pleased with ... plan to report data from the Phase 2/3 study in ... of dosing and are now receiving ISIS-TTR Rx in ...
(Date:3/2/2015)... , March 2, 2015 The Economist ... London last week on 26 February was host to ... on a number of topical issues facing the sector. This year,s ...   E ra , , observed the challenges the ... them. Panel speakers offered contrasting and thought-provoking commentary on ...
Breaking Medicine Technology:SI-BONE, Inc. Announces 15,000 iFuse Procedure Milestone 2SI-BONE, Inc. Announces 15,000 iFuse Procedure Milestone 3Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx 2Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx 321 Years of Debate: The Pharmaceutical Industry Convenes at The Economist Events' Pharma Summit 2015 to Discuss The Dawn of a New Era for the Industry 221 Years of Debate: The Pharmaceutical Industry Convenes at The Economist Events' Pharma Summit 2015 to Discuss The Dawn of a New Era for the Industry 321 Years of Debate: The Pharmaceutical Industry Convenes at The Economist Events' Pharma Summit 2015 to Discuss The Dawn of a New Era for the Industry 421 Years of Debate: The Pharmaceutical Industry Convenes at The Economist Events' Pharma Summit 2015 to Discuss The Dawn of a New Era for the Industry 521 Years of Debate: The Pharmaceutical Industry Convenes at The Economist Events' Pharma Summit 2015 to Discuss The Dawn of a New Era for the Industry 6
... 7, 2011 Inovio Pharmaceuticals, Inc. (NYSE Amex: ... therapeutic and preventive vaccines against cancers and infectious diseases, ... technology, which provides the powerful enabling capabilities of electroporation ... published in the scientific journal Human Vaccines . ...
... 2011 Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ... $230 million aggregate principal amount of 4.75% Convertible Senior ... of Notes sold reflects the full exercise by the ... amount of Notes to cover over-allotments. The ...
Cached Medicine Technology:Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery 2Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery 3Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery 4Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery 5Savient Closes Sale of $230 Million in Convertible Senior Notes 2
Inquire...
... The AB5000 Circulatory Support System consists of ... advanced computer system that drives the blood pumps ... or for transport of patients between hospitals. The ... of supporting the left, right, or both ventricles ...
... rapid test is a qualitative one ... a conation of monoclonal,antibody/colloidal gold dye ... on the solid phase. This will ... typhi (typhoid) infection with a high ...
... InstaTest Mono is an immunochromatographic in ... associated with,infectious mononucleosis infection.,Infectious mononucleosis (IM) ... diagnosis of IM is based on ... infection, such as the,heterophile antibodies present ...
Medicine Products: